Netherlands Pharmaceutical Market Size (2024 - 2029)

Netherlands Pharmaceutical Market Analysis

The Netherlands Pharmaceutical Market size is estimated at USD 9.92 billion in 2024, and is expected to reach USD 14.24 billion by 2029, growing at a CAGR of 7.5% during the forecast period (2024-2029).

The COVID-19 pandemic had a significant impact on the market in its early phase due to various lockdown regulations that were imposed. For instance, according to an article published by PubMed Central in January 2021, a cross-sectional study was performed, which showed that there was a considerable impact of the COVID-19 pandemic on both logistic procedures and services in the pharmacies of the Netherlands. The reduction in such services meant fewer pharmaceutical sales. Hence, the COVID-19 pandemic had a significant impact on the market initially. However, post pandemic the market studied is expected to have stable growth during the forecast period of the study.

The presence of world-class research institutes, a highly educated workforce, an excellent healthcare system, and an innovation-friendly government, combined with a central location, makes the country an ideal base for biopharmaceutical operations. Healthcare and medical spending have increased over the past few years, reflecting strong potential for new medicine development, infrastructure building, and new entry/expansion opportunities. At the same time, the government is taking various initiatives to lower the prices of pharmaceutical products, which is expected to have adverse effects on the profitability of pharmaceutical companies. The Netherlands is expected soon negotiate lowering drug prices with pharmaceutical companies.

As per the data published by the Dutch Cancer Society (KWF), in 2021, cancer was the leading cause of death in the Netherlands. According to the same data, in 2021, an estimated 44,996 persons died of cancer, out of which 24,266 were men, and 20,730 were women. Furthermore, according to the data published by the World Bank, in 2022, the prevalence of diabetes as a percentage of the population aged between 20 and 79 was 4.5% in the Netherlands in 2021. Hence with the increasing burden of various diseases, it is expected that there will be steady growth in the market.

Therefore, owing to the aforementioned factors, the market is anticipated to witness growth over the forecast period. However, the high failure rate and developing cost of new products are likely to impede the growth of the market.

Netherlands Pharmaceutical Industry Segmentation

Pharmaceuticals are referred to as prescribed and non-prescribed drugs. These medicines can be bought by an individual with or without the doctor's prescription and are safe for consumption for various illnesses with or without the doctor's consent. The report also covers an in-depth analysis of qualitative and quantitative data. The Dutch pharmaceutical market is segmented by ATC/therapeutic class (alimentary tract and metabolism, blood and blood-forming organs, cardiovascular system, dermatological drugs, genitourinary system and reproductive hormones, systemic hormonal preparations, excluding reproductive hormones and Insulins, antiinfectives for systemic use, antineoplastic and immunomodulating agents, musculoskeletal system, nervous system, antiparasitic products, insecticides and repellents, respiratory system, sensory organs, and various ATC structure), and mode of dispensing (Prescription and OTC). The report offers values in USD million for all the above-mentioned segments.